Veritas Pharma

Bureau Veritas is in exclusive negotiations with Triton Partners to sell its oil, petrochemicals and coal inspection unit; the transaction has an enterprise value of €470m (EV/EBIT 11.1 on expected 2025 results). The unit generated around €450m in revenue in 2025, grew more slowly than the group and diluted operating margins, so the sale is part of the LEAP|28 portfolio-rotation plan. Barclays confirmed an "Overweight" rating with a €31.00 price target, while RBC kept "Sector Perform" and a €26.00 target. The announcement, positive analyst comments and a favorable market backdrop pushed the stock about 1% to €26.30, still below the 52-week high of €29.42. » More on de.investing.com

Bureau Veritas reported Q1 2026 revenue of €1.55bn, missing expectations of €1.56bn (-0.64%). Organic growth was 4.5%, driven by the Shipping & Offshore segment (+11.2%), but was heavily hit by negative currency effects of -5.2%. After the figures the share fell 11.66% to €28.61. Management expects waning currency headwinds from Q2, points to a robust order book and confirms mid‑term EPS and revenue targets, but sees risks from currency volatility, project delays and geopolitical tensions. » More on de.investing.com